3,5-dihydroxy-7,3',4',5'-tetramethoxyflavone for COVID-19
c19early.org
COVID-19 Treatment Clinical Evidence
COVID-19 involves the interplay of 400+ viral and host proteins and factors, providing many therapeutic targets.
c19early analyzes 6,000+ studies for 210+ treatments—over 17 million hours of research.
Only three high-profit early treatments are approved in the US.
In reality, many treatments reduce risk,
with 25 low-cost treatments approved across 163 countries.
-
Naso/
oropharyngeal treatment Effective Treatment directly to the primary source of initial infection. -
Healthy lifestyles Protective Exercise, sunlight, a healthy diet, and good sleep all reduce risk.
-
Immune support Effective Vitamins A, C, D, and zinc show reduced risk, as with other viruses.
-
Thermotherapy Effective Methods for increasing internal body temperature, enhancing immune system function.
-
Systemic agents Effective Many systemic agents reduce risk, and may be required when infection progresses.
-
High-profit systemic agents Conditional Effective, but with greater access and cost barriers.
-
Monoclonal antibodies Limited Utility Effective but rarely used—high cost, variant dependence, IV/SC admin.
-
Acetaminophen Harmful Increased risk of severe outcomes and mortality.
-
Remdesivir Harmful Increased mortality with longer followup. Increased kidney and liver injury, cardiac disorders.
3,5-dihydroxy-7,3',4',5'-tetramethoxyflavone may be beneficial for
COVID-19 according to the study below.
COVID-19 involves the interplay of 400+ viral and host proteins and factors providing many therapeutic targets.
Scientists have proposed 11,000+ potential treatments.
c19early.org analyzes
210+ treatments.
We have not reviewed 3,5-dihydroxy-7,3',4',5'-tetramethoxyflavone in detail.
, Inhibition Potential of Quercetin Similar Compounds to SARS‐CoV‐2 Main Protease by High‐Throughput Virtual Screening, Molecular Simulations, ADMET Analysis, and DFT Studies, Chemistry & Biodiversity, doi:10.1002/cbdv.202501485
ABSTRACTThis study focused on in silico investigation of SARS‐CoV‐2 Mpro inhibitors screened from 6663 quercetin similar compounds. Two promising compounds, blumeatin B (L1) and 3,5‐dihydroxy‐7,3′,4′,5′‐tetramethoxyflavone (L2), were identified through machine learning based virtual screening and similarity analysis. They underwent molecular docking with Mpro and demonstrated strong interactions, with docking scores of −8.02 and −7.21 kcal/mol, respectively. Various parameters (RMSD, RMSF, Rg, SASA, and the number of hydrogen bonds) observed during 200 ns molecular dynamics (MD) simulation confirmed their stability. Principal component analysis (PCA) and dynamical cross‐correlation matrix (DCCM) revealed minimal conformational changes and strongly correlated motions in the protein. End‐state MM/GBSA free energy calculations for L1 and L2 with Mpro were −22.86 and −19.89 kcal/mol. Density functional theory (DFT) studies at the B3LYP/6‐311++G (d,p) level showed their polar nature, with electrophilicity index values exceeding 1.5 eV. The HOMO–LUMO energy gaps of L1 and L2 were 4.04 and 3.57 eV, aligning with the DOS spectra. Based on results from virtual screening, ADMET parameters, docking scores, hydrophobic interactions, hydrogen bonding, MD simulation, end‐state free energy calculations, and DFT findings, L1 and L2 could be considered as promising SARS‐CoV‐2 Mpro inhibitors, requiring further experimental validation.